Have increased knowledge regarding the:<br> Cut-off values for use of noninvasive tests to assess liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)<br> Clinical data on novel therapies for MASH
Have greater competence related to evaluating liver fibrosis in patients with MASH
Demonstrate greater confidence in their ability to assess for liver fibrosis using noninvasive tests